BeyondSpring Inc. Logo

BeyondSpring Inc.

Develops innovative immuno-oncology cancer therapies, including a 'pipeline in a drug' asset.

BYSI | NDAQ

Overview

Corporate Details

ISIN(s):
KYG108301006
LEI:
Country:
United States of America
Address:
100 CAMPUS DRIVE, WEST SIDE, 4TH FLOOR, 7932 FLORHAM PARK
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

BeyondSpring Inc. is a global, clinical-stage biopharmaceutical company focused on developing innovative immuno-oncology cancer therapies. The company is committed to improving clinical outcomes and raising the standard of care for cancer patients. Its lead asset, Plinabulin, is being developed as a 'pipeline in a drug' for multiple cancer indications. BeyondSpring is also an equity owner of SEED Therapeutics, a company specializing in Targeted Protein Degradation (TPD) technology to discover and develop novel 'molecular glues' for breakthrough therapeutics.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all BeyondSpring Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for BeyondSpring Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for BeyondSpring Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Organoid-based platforms for drug testing and regenerative therapeutics.
South Korea 476040
Oricon Inc. Logo
Provides entertainment industry data, music charts, web media, and marketing services.
Japan 4800
ORIENTBIO Inc. Logo
Provides animal models & technical services for preclinical R&D to pharma & research institutions.
South Korea 002630
Oryzon Genomics S.A. Logo
Develops epigenetic-based medicines for cancer and central nervous system disorders.
Spain ORY
OSCOTECInc. Logo
A clinical-stage drug discovery company developing innovative medicines for unmet needs.
South Korea 039200
OSE Immunotherapeutics Logo
Develops first-in-class immune therapies for oncology and inflammation, partnering for late-stage.
France OSE
Oxurion NV Logo
Acquires European pharmaceutical subcontractors to build an integrated healthcare services group.
Belgium OXUR
PA Co., Ltd Logo
Offers HR solutions like recruitment media, staffing, and childcare to revitalize local communities.
Japan 4766
Passage BIO, Inc. Logo
Developing genetic medicines for severe CNS and neurodegenerative disorders.
United States of America PASG
PCI Biotech Holding Logo
Biopharma firm evaluating its future after discontinuing its core technology development.
Norway PCIB

Talk to a Data Expert

Have a question? We'll get back to you promptly.